AdmitHub

ADmit Therapeutics is a biotechnology company based in Barcelona, Spain, specializing in the development of early diagnostic and prognostic tests for Alzheimer's disease. The company's flagship product, the MAP-AD Test, utilizes next-generation sequencing (NGS) and proprietary AI algorithms to analyze epigenetic biomarkers—specifically mitochondrial DNA (mtDNA) methylation—in blood samples. This non-invasive approach allows for the identification of patients at high risk of progressing to Alzheimer's dementia, even in the early stages of mild cognitive impairment (MCI). By providing a reliable prognostic tool, ADmit Therapeutics aims to optimize patient stratification for clinical trials and enable personalized treatment strategies. The company is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL) and is currently located within Almirall's Innovation Hub.